Abstract: The present invention relates to a holding device for screwing in a screw, which relates to a device used to facilitate screwing a screw into a surface by means of an electric or manual screwdriver. The device comprises a continuous body with a characteristic outer surface and a bore communicating a top opening with a bottom opening of the body, the bore having a series of elastic longitudinal ribs. The device facilitates the positioning, tightening, guidance and release of the screw and the screwdriver, even in hard-to-reach places.

Abstract: The technology described in this document can be embodied in a computer-implemented method that includes receiving, at a processing system, a first signal including an output of a speaker device and an additional audio signal. The method also includes determining, by the processing system, based at least in part on a model trained to identify the output of the speaker device, that the additional audio signal corresponds to an utterance of a user. The method further includes initiating a reduction in an audio output level of the speaker device based on determining that the additional audio signal corresponds to the utterance of the user.

Abstract: Process for the enzymatic synthesis of the compound of formula (I), (7S)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)N-methyl methanamine: and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.

Abstract: A laser system is calibrated with a tomography system capable of measuring locations of structure within an optically transmissive material such as a tissue of an eye. Alternatively or in combination, the tomography system can be used to track the location of the eye and adjust the treatment in response to one or more of the location or an orientation of the eye. In many embodiments, in situ calibration and tracking of an optically transmissive tissue structure such as an eye can be provided. The optically transmissive material may comprise one or more optically transmissive structures of the eye, or a non-ocular optically transmissive material such as a calibration gel in a container or an optically transmissive material of a machined part.

Abstract: The present invention is related to a microencapsulated bacterial consortium for gluten degradation, which comprises: a) three different strains of commercially available lactic-acid bacteria; b) encapsulating agents; c) prebiotics; and d) trehalose; in combination with a proteolytic enzyme of bacterial origin and a proteolytic enzyme of fungal origin. Preferably, the microencapsulated bacterial consortium comprises: a) Lactobacillus plantarum ATCC 8014; b) Lactobacillus sanfranciscensis ATCC 27652; c) Lactobacillus brevis ATCC 14869; d) isolated protein from milk serum with 90% protein; e) maltodextrin with a dextrose equivalent of 10; f) arabic gum; g) maguey honey; and h) trehalose; in combination with a protease of bacterial origin and a protease of fungal origin. It also describes a process for obtaining the microencapsulated bacterial consortium, as well as the preparation of sourdoughs therefrom, and the use of said sourdoughs to obtain baking products.

Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.

Abstract: The present invention generally relates to receiving bodily fluid through a device opening. In one aspect, the device includes a flow activator arranged to cause fluid to be released from a subject. A deployment actuator may actuate the flow activator in a deployment direction, which may in turn cause fluid release from a subject. The flow activator may also be moved in a retraction direction by a retraction actuator. In one aspect, the device may include a vacuum source that may help facilitate fluid flow into the opening of the device and/or may help facilitate fluid flow from the opening to a storage chamber. In one aspect, a device actuator may enable fluid communication between the opening and the vacuum source and the flow activator may be actuated after the enablement of fluid communication.

Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.

Abstract: A laser eye surgery system focuses light along a beam path to a focal point having a location within a lens of the eye. The refractive index of the lens is determined in response to the location. The lens comprises a surface adjacent a second material having a second refractive index. The beam path extends a distance from the surface to the focal point. The index is determined in response to the distances from the surface to the targeted focal point and from the surface to the actual focal point, which corresponds to a location of a peak intensity of an optical interference signal of the focused light within the lens. The determined refractive index is mapped to a region in the lens, and may be used to generate a gradient index profile of the lens to more accurately place laser beam pulses for incisions.

Abstract: Methods and apparatus are configures to measure an eye without contacting the eye with a patient interface, and these measurements are used to determine alignment and placement of the incisions when the patient interface contacts the eye. The pre-contact locations of one or more structures of the eye can be used to determine corresponding post-contact locations of the one or more optical structures of the eye when the patient interface has contacted the eye, such that the laser incisions are placed at locations that promote normal vision of the eye. The incisions are positioned in relation to the pre-contact optical structures of the eye, such as an astigmatic treatment axis, nodal points of the eye, and visual axis of the eye.

Abstract: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.

Abstract: A densitometer includes a plurality of light-emitting diodes (LEDs) and at least one sensor. The LEDs are activated one at a time in a sequential, repeatable order. Photonic energy from each LED is reflected off an entity and is incident upon the sensor(s). Circuitry samples or acquires signaling from the sensor(s) in accordance with the respective LED activations. Signaling from the densitometer can be used in controlling ink-jetting printers or other apparatus.

Abstract: A fiducial is generated on an internal anatomical structure of the eye of a patient with a surgical laser. A tonic artificial intraocular lens (IOL) is positioned so that a marker of the tonic IOL is in a predetermined positional relationship relative to the fiducial. This positioning aligns the tonic IOL with the astigmatic or other axis of the eye. The toric IOL is then implanted in the eye of the patient with high accuracy.

Abstract: The invention relates to a simulation and planning system for intraoperative radiation therapy and to a method allowing said system to be used for treatment studies, simulation, planning, training and recording, which system generally comprises a central processing unit or computer (1) for management and control and software-based communication with the rest of the devices and the user; one or several monitors or screens (2) for displaying images and peripherals responsible for gathering data relating to the actions performed by said user, a deformation simulation module for the virtual simulation of the deformation produced in the organs and tissues during the process; algorithms for instantly calculating the radiation dose applied during the radiation therapy treatment simulation and means for recording all the activities carried out and generating a full dosimetry report.

Abstract: Printhead control systems and methods for controlling a printhead A printhead control system comprises a voltage supply control module to selectively supply an operating voltage to a printhead, and the voltage supply control module is configured to receive a first and a second control voltages, and to disconnect the supply of operating voltage to the printhead at least when the first and second control voltages have the same logical level.

Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.

Abstract: The subject invention provides a flight simulator, having a folded state and an unfolded state, having a chassis, an inner display and support that may be stowed or deployed, and an outer display and support that may be stowed or deployed.

Abstract: Disclosed embodiments include a method and an apparatus for digital content transmission that comprise: (a) partitioning the digital content into a plurality of sequential segments; (b) selecting a plurality of transmission time instants for each of the sequential segments as a function of their order; (c) generating a plurality of linear combinations of the plurality of sequential segments during the plurality of transmission time instants resulting in a plurality of linearly combined coded segments; and (c) transmitting the plurality of linearly combined coded segments from a server to a plurality of clients. In particular embodiments, the method and apparatus further comprise performing error correction based on an implicit error correction (IEC) method that employs the redundancy present in the linearly combined coded segments to perform error correction at the client side without extra bandwidth cost.

Abstract: A heavy truck frame (18) and a method for manufacturing a heavy truck frame having side-rails (20, 24) with a configuration of a top C-section (30) and a bottom C-section (32) and a vertical insert (34) so as to reduce weight and maintain the stiffness requirements and improve payload. The optimal distances between a top C-section (30) and a bottom C-section (32) can vary according to the part of the frame and vehicle requirements.

Abstract: The present invention generally relates to receiving bodily fluid through a device opening. In one aspect, the device includes a flow activator arranged to cause fluid to be released from a subject. A deployment actuator may actuate the flow activator in a deployment direction, which may in turn cause fluid release from a subject. The flow activator may also be moved in a retraction direction by a retraction actuator. In one aspect, the device may include a vacuum source that may help facilitate fluid flow into the opening of the device and/or may help facilitate fluid flow from the opening to a storage chamber. In one aspect, a device actuator may enable fluid communication between the opening and the vacuum source and the flow activator may be actuated after the enablement of fluid communication.